Sensei biotherapeutics announces prioritization of next-generation multi-antigenic immunophage platform, monoclonal antibody and nanobody programs

- company to focus on development of next-generation phage product candidates from immunophage platform and monoclonal antibody and nanobody programs -

SNSE Ratings Summary

SNSE Quant Ranking